13F Holdings
中文EN

LCTX Lineage Cell Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 876343 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.2%
TTM net income YoY102.6%
TTM EPS YoY69.0%
Revenue 3-yr CAGR7.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-280.3%
Net margin16.2%
FCF margin-244.1%
EBITDA margin-273.3%

Returns

ROE3.9%
ROA1.8%
ROIC (approx.)-216.8%
Asset turnover0.11x

Leverage & solvency

Liabilities / assets34.1%
Debt / equity0.00x
Current ratio5.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-14.73x
Accruals ratio29.1%
Payout ratio—
Capex / revenue5.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$14.56M$9.50M$8.95M$14.70M$4.34M
Cost of revenue—$334,000$671,000$728,000$1.43M
Gross profit—$9.16M$8.27M$13.97M$2.92M
R&D expense$17.73M$12.47M$15.71M$13.99M$33.91M
SG&A expense$18.46M$18.17M$17.30M$22.51M$18.21M
Operating income-$36.62M-$21.48M-$24.73M-$22.52M-$49.21M
Pretax income-$68.65M-$18.58M-$23.28M-$25.81M-$43.27M
Income tax-$5.28M$0-$1.80M$541,000—
Net income-$63.53M-$18.61M-$21.49M-$26.27M-$43.02M
EBITDA-$35.92M-$20.89M-$24.17M-$21.94M-$48.55M
EPS (basic)-0.28-0.09-0.12-0.15-0.26
EPS (diluted)-0.28-0.09-0.12-0.15-0.26
Weighted avg. shares (diluted)230.12M200.19M172.66M169.79M164,502
Banking
Net interest income———$829,000$2,000
Balance sheet
Cash & equivalents$40.79M$46.35M$35.99M$11.94M$56.28M
Short-term investments$14.99M$2.02M$50,000$46.52M$2.62M
Receivables$891,000$638,000$745,000$297,000$50.60M
Current assets$59.16M$51.00M$38.44M$60.00M$111.55M
PP&E, net$2.57M$2.25M$2.25M$5.67M$4.87M
Goodwill$10.67M$10.67M$10.67M$10.67M$10.67M
Intangibles$31.70M$46.54M$46.56M$46.69M$46.82M
Total assets$112.58M$113.22M$101.02M$123.66M$174.54M
Current liabilities$11.37M$13.98M$17.96M$18.98M$47.12M
Total liabilities$69.24M$36.21M$39.00M$51.73M$83.65M
Shareholders' equity$44.55M$78.38M$63.42M$73.34M$92.22M
Shares outstanding243.12M220.42M174.99M170.09M169.48M
Cash flow statement
Operating cash flow-$18.92M-$23.09M-$28.57M$1.06M-$23.56M
Capital expenditure$522,000$565,000$674,000$413,000$340,000
Free cash flow-$19.44M-$23.66M-$29.24M$646,000-$23.90M
Investing cash flow-$13.46M-$2.31M$46.45M-$46.16M$9.74M
Financing cash flow$26.95M$35.86M$6.42M$1.63M$36.93M
Depreciation & amortization$699,000$587,000$562,000$582,000$663,000
Stock-based compensation$4.75M$5.08M$4.64M$4.29M$3.52M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.